aTyr Pharma (NASDAQ:LIFE – Get Rating) and Gene Biotherapeutics (OTCMKTS:CRXM – Get Rating) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, earnings, profitability, dividends and analyst recommendations.

Analyst Ratings

This is a breakdown of recent ratings and price targets for aTyr Pharma and Gene Biotherapeutics, as reported by MarketBeat.com.

aTyr Pharma currently has a consensus target price of $14.00, indicating a potential upside of 514.04%.

Profitability

Earnings & Valuation

This table compares aTyr Pharma and Gene Biotherapeutics' revenue, earnings per share and valuation.

Gene Biotherapeutics has lower revenue, but higher earnings than aTyr Pharma.

Institutional & Insider Ownership

65.6% of aTyr Pharma shares are held by institutional investors. 4.4% of aTyr Pharma shares are held by insiders. Comparatively, 49.8% of Gene Biotherapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Volatility and Risk

aTyr Pharma has a beta of 1.31, suggesting that its stock price is 31% more volatile than the S&P 500. Comparatively, Gene Biotherapeutics has a beta of 0.73, suggesting that its stock price is 27% less volatile than the S&P 500.

About aTyr Pharma

(Get Rating)

aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. The company's lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase II clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. It is also developing ATYR2810, a fully humanized monoclonal antibody that is in preclinical development for the treatment of solid tumors. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. The company was incorporated in 2005 and is headquartered in San Diego, California.

About Gene Biotherapeutics

(Get Rating)

Gene Biotherapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of angiogenic gene therapy biotherapeutics for the treatment of cardiovascular diseases in the United States. The company's lead product candidate is Generx, an angiogenic gene therapy product candidate in Phase 3 clinical trials for the potential treatment of patients with myocardial ischemia and refractory angina due to advanced coronary artery disease. It is also developing Generx for ischemia-related cardiovascular and cerebral therapeutic indications. Gene Biotherapeutics, Inc. has an agreement with Fujifilm Diosynth Biotechnologies for the manufacture of Generx angiogenic gene therapy product for Phase 3 clinical evaluation. The company was formerly known as Taxus Cardium Pharmaceuticals Group, Inc. and changed its name to Gene Biotherapeutics, Inc. in January 2018. Gene Biotherapeutics, Inc. was incorporated in 2003 and is headquartered in San Diego, California.

Receive News & Ratings for aTyr Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for aTyr Pharma and related companies with MarketBeat.com's FREE daily email newsletter.